Zyprexa Could Gain From CATIE Cost/Benefit Analysis, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.